Cite
HARVARD Citation
Phisalprapa, P. et al. (2020). Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand. Journal of medical economics. pp. 1302-1310. [Online].